BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

FRA:22UA • US09075V1026

93.45 EUR
+2 (+2.19%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

22UA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. The financial health of 22UA is average, but there are quite some concerns on its profitability. 22UA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year 22UA has reported negative net income.
  • In the past year 22UA has reported a negative cash flow from operations.
  • 22UA had positive earnings in 4 of the past 5 years.
  • 22UA had a positive operating cash flow in 4 of the past 5 years.
22UA.DE Yearly Net Income VS EBIT VS OCF VS FCF22UA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

  • The Return On Assets of 22UA (-2.68%) is better than 67.95% of its industry peers.
  • 22UA's Return On Equity of -3.09% is fine compared to the rest of the industry. 22UA outperforms 73.08% of its industry peers.
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
22UA.DE Yearly ROA, ROE, ROIC22UA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

  • With a decent Gross Margin value of 85.62%, 22UA is doing good in the industry, outperforming 78.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 22UA has remained more or less at the same level.
  • 22UA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
22UA.DE Yearly Profit, Operating, Gross Margins22UA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • 22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 22UA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 22UA has been increased compared to 5 years ago.
  • Compared to 1 year ago, 22UA has a worse debt to assets ratio.
22UA.DE Yearly Shares Outstanding22UA.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
22UA.DE Yearly Total Debt VS Total Assets22UA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • An Altman-Z score of 6.59 indicates that 22UA is not in any danger for bankruptcy at the moment.
  • 22UA has a Altman-Z score of 6.59. This is amongst the best in the industry. 22UA outperforms 80.77% of its industry peers.
  • 22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.01, 22UA is doing good in the industry, outperforming 78.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.59
ROIC/WACCN/A
WACC7.42%
22UA.DE Yearly LT Debt VS Equity VS FCF22UA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • 22UA has a Current Ratio of 7.12. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 7.12, 22UA belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
  • 22UA has a Quick Ratio of 7.02. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.
  • 22UA's Quick ratio of 7.02 is amongst the best of the industry. 22UA outperforms 88.46% of its industry peers.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 7.02
22UA.DE Yearly Current Assets VS Current Liabilites22UA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for 22UA have decreased strongly by -20.92% in the last year.
  • 22UA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
  • The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%

3.2 Future

  • Based on estimates for the next years, 22UA will show a small growth in Earnings Per Share. The EPS will grow by 5.52% on average per year.
  • 22UA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.93% yearly.
EPS Next Y-19.54%
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%
EPS Next 5Y5.52%
Revenue Next Year4.52%
Revenue Next 2Y0.54%
Revenue Next 3Y0.98%
Revenue Next 5Y0.93%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
22UA.DE Yearly Revenue VS Estimates22UA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
22UA.DE Yearly EPS VS Estimates22UA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 22UA. In the last year negative earnings were reported.
  • Also next year 22UA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
22UA.DE Price Earnings VS Forward Price Earnings22UA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
22UA.DE Per share data22UA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • A cheap valuation may be justified as 22UA's earnings are expected to decrease with -6.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 22UA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIONTECH SE-ADR

FRA:22UA (2/20/2026, 7:00:00 PM)

93.45

+2 (+2.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-10
Inst Owners22.81%
Inst Owner ChangeN/A
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap22.47B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts82.14
Price Target120.71 (29.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)1.19%
PT rev (3m)3.36%
EPS NQ rev (1m)-103.05%
EPS NQ rev (3m)86.74%
EPS NY rev (1m)-0.57%
EPS NY rev (3m)30.88%
Revenue NQ rev (1m)-0.88%
Revenue NQ rev (3m)-2.94%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)24.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.13
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)-4.55
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS13.11
BVpS76.84
TBVpS69.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.68%
ROE -3.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.62%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 202.92%
Cap/Sales 24.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 7.02
Altman-Z 6.59
F-Score3
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-19.54%
EPS Next 2Y-13.54%
EPS Next 3Y-6.16%
EPS Next 5Y5.52%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year4.52%
Revenue Next 2Y0.54%
Revenue Next 3Y0.98%
Revenue Next 5Y0.93%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.76%
EBIT Next 3Y9.31%
EBIT Next 5Y19.64%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A

BIONTECH SE-ADR / 22UA.DE FAQ

What is the ChartMill fundamental rating of BIONTECH SE-ADR (22UA.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE.


What is the valuation status for 22UA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (22UA.DE). This can be considered as Overvalued.


Can you provide the profitability details for BIONTECH SE-ADR?

BIONTECH SE-ADR (22UA.DE) has a profitability rating of 3 / 10.


What is the financial health of BIONTECH SE-ADR (22UA.DE) stock?

The financial health rating of BIONTECH SE-ADR (22UA.DE) is 6 / 10.